List view / Grid view
At AAIC 2024, AC Immune unveiled a new class of antibody drug conjugates, called morADC (Morphomer® antibody drug conjugate). In this Q&A, CEO of AC Immune, Andrea Pfeifer, discusses how morADC uses the capabilities of the company’s two discovery platforms to combine two highly selective molecules, resulting in drug candidates…
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
As COVID-19 continues to evolve, researchers are still on the lookout for new ways to protect against the virus. Drug Target Review brings you some of the most recent pre-clinical developments.
Drug Target Review’s Ria Kakkad recently spoke with Dr Jane Osbourn about her experience as a woman in STEM.
Researchers find monoclonal antibodies provided nearly complete protection against EBV infection and lymphoma when tested in mice.
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
A recently discovered SARS-CoV-2 virus in a Russian bat is likely to be capable of infecting humans and resistant to current vaccines.
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
While the introduction of novel immunotherapies to combat and treat cancer has advanced patient care greatly, ever more effective solutions continue to be required. Here, Dr Edmond Chan, Senior Director, EMEA Therapeutic Area Lead, Haemato-Oncology at Janssen Europe, Middle East & Africa (EMEA), explores how T-cell redirecting bispecific antibodies (TRBAs)…
In this exclusive Q&A, Dr Veysel Kayser, Associate Professor at the University of Sydney, Australia, outlines why monoclonal antibodies (mAbs) are such an important tool to combat cancer. He also relates his recent research, as well as the latest trends in the industry.
In this ebook are articles on why monoclonal antibodies represent a high level of promise in the fight against cancer and how T-cell redirecting bispecific antibodies could work as a new immunotherapeutic strategy against haematological conditions.
The monoclonal antibody 19A11 binds E-cadherin, a protein that helps cells stick together, especially in epithelial layers that line the skin, the gut and other organs.
The scientists found that the neutralising monoclonal antibody protected against SARS-CoV-2 infections in animal experiments.
Listen to this podcast to discover why mAbs are key in the fight against SARS-CoV-2 and how the pandemic has shaped their development pipeline.
